首页 内克塔疗法(usNKTR)-基本信息

内克塔疗法(usNKTR)-基本信息

日报更新时间:

周报更新时间:04-11 03:39

行情信息

今开价:18.55

最高价:19.0

成交量:644498.0

昨收价:18.63

最低价:18.14

最新价:18.68

行情图标
概要信息

中文名称:内克塔疗法


英文名称:Nektar Therapeutics


行业:医疗


简介:Nektar Therapeutics于1990年在加州成立,并于1998年重新在特拉华州注册


电话:1-415-4825300


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Nektar Therapeutics产品线包括肿瘤、疼痛、抗感染药和免疫学治疗领域的候选药物,内克塔治疗公司产品包括: MOVANTIK(商用阶段)——一种口腔外周发挥作用μ-阿片拮抗剂,用于治疗成人便秘,具有泻药的作用; Etirinotecan Pegol(临床阶段)——拓扑异构酶I抑制剂,用于转移性乳腺癌治疗III期临床试验阶段,以及铂抗性/难治的卵巢癌和二线转移性结直肠癌的II期临床试验阶段。并与5-氟尿嘧啶/亚叶酸组合来治疗胃肠相关实体瘤,目前已完成I期临床试验; BAX 855(临床阶段)——用于治疗A型血友病,目前处于III期临床试验阶段; BAY41-6551(临床阶段)——用于治疗革兰氏阴性菌肺炎,目前处于III期临床试验阶段; NKTR-181(临床阶段)——用于治疗慢性疼痛,目前处于III期临床试验阶段; NKTR-171(临床阶段)——用于治疗神经性疼痛,目前处于I期临床试验阶段; NKTR-214(临床阶段)——用于治疗癌症,目前处于临床前试验阶段。内克塔治疗(Nektar Therapeutics)与29家以上的制药公司和生物技术公司合作,包括:Baxter Healthcare、Bayer Healthcare LLC、AstraZeneca AB.、Amgen Inc.、Allergan, Inc.、Halozyme Therapeutics, Inc.、Merck & Co., Inc.、Ophthotech Corporation、Pfizer, Inc.、F. Hoffmann-La Roche Ltd (Roche)、UCB Pharma等。

交易日期 交易人 职位 类型 交易份额 价格
2019-07-24 Robin (Howard W) Chief Executive Officer Sell 33333 29.65
2019-07-24 Robin (Howard W) Chief Executive Officer Buy 33333 7.21
2019-07-23 Robin (Howard W) Chief Executive Officer Sell 33334 32.11
2019-07-23 Robin (Howard W) Chief Executive Officer Buy 33334 7.21
2019-07-22 Robin (Howard W) Chief Executive Officer Buy 33333 7.21
2019-07-22 Robin (Howard W) Chief Executive Officer Sell 33333 32.10
2019-07-09 Labrucherie (Gilbert M JR) Chief Financial Officer Buy 25000 7.21
2019-07-09 Labrucherie (Gilbert M JR) Chief Financial Officer Sell 25000 34.57
2019-07-07 Lingnau (Lutz) Director Sell 10000 34.63
2019-07-07 Lingnau (Lutz) Director Buy 10000 9.24
2019-06-16 Labrucherie (Gilbert M JR) Chief Financial Officer Sell 25000 33.71
2019-06-16 Labrucherie (Gilbert M JR) Chief Financial Officer Buy 25000 7.21
2019-05-22 Robin (Howard W) Chief Executive Officer Buy 33333 7.21
2019-05-22 Robin (Howard W) Chief Executive Officer Sell 33333 32.69
2019-05-21 Robin (Howard W) Chief Executive Officer Sell 33334 33.38
2019-05-21 Robin (Howard W) Chief Executive Officer Buy 33334 7.21
2019-05-20 Robin (Howard W) Chief Executive Officer Buy 33333 7.21
2019-05-20 Robin (Howard W) Chief Executive Officer Sell 33333 32.93
2019-05-15 Robin (Howard W) Chief Executive Officer Sell 13383 31.37
2019-05-15 Doberstein (Stephen K) Officer Sell 3461 31.37
2019-05-15 Nicholson (John L) Chief Operating Officer Sell 4077 31.37
2019-05-15 Labrucherie (Gilbert M JR) Chief Financial Officer Sell 3767 31.37
2019-05-15 Hora (Maninder) Officer Sell 2449 31.37
2019-05-15 Thomsen Jillian B Officer Sell 1928 31.37
2019-03-07 Greer (R Scott) Director Buy 10000 5.14

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
BB Biotech AG 2020676 1.16% 639701 46.32% 2019-03-31
BlackRock Inc 12515343 7.18% -463835 -3.57% 2019-03-31
Wellington Management Company LLP 12961558 7.44% 2220193 20.67% 2019-03-31
OppenheimerFunds Inc 17302891 9.93% -34 -- 2019-03-31
Vanguard Group Inc 18156579 10.42% -147952 -0.81% 2019-03-31
PRIMECAP Management Company 19355822 11.10% -44200 -0.23% 2019-03-31
Fidelity Management and Research Company 20167742 11.57% -5122799 -20.26% 2019-03-31
FMR Inc 20426894 11.72% -5534626 -21.32% 2019-03-31
Invesco Ltd (OFI / OppenheimerFunds) 21771670 12.49% 442062 2.07% 2019-07-31
Fidelity Management & Research Company 12024263 6.90% -2697811 -18.32% 2019-07-31
BlackRock Fund Advisors 10590389 6.08% -6384457 -37.61% 2019-07-31
State Street Corporation 7098904 4.07% 308472 4.54% 2019-03-31
Bellevue Asset Management AG 2138476 1.23% 64280 3.10% 2019-07-31
First Trust Advisors L.P. 2149180 1.23% -159992 -6.93% 2019-03-31
Geode Capital Management, LLC 2398081 1.38% -2070311 -46.33% 2019-03-31
HHG PLC 2462860 1.41% -64101 -2.54% 2019-03-31
State Street Global Advisors 2786441 1.60% 3448 0.12% 2019-07-31
Fidelity SelectCo, LLC 2983700 1.71% -515773 -14.74% 2019-07-31
Fidelity Management Trust Co 4344206 2.49% -29793 -0.68% 2019-07-31
Vanguard Investments Australia Ltd 4853860 2.78% -14341 -0.29% 2019-07-31
BlackRock Japan Co Ltd 2561904 1.47% -34990 -1.35% 2019-05-31
BlackRock Asset Management Canada Ltd 5435526 3.12% 6807 0.13% 2019-05-31
OFI Global Asset Management, Inc. 17300000 9.93% -99564 -0.57% 2019-04-30
SSGA Funds Management Inc 2099818 1.20% -184106 -8.06% 2019-04-30
Camber Capital Management LLC 2000000 1.15% 500000 33.33% 2018-12-31
State Street Global Advisors (Aus) Ltd 1904378 1.10% -65611 -3.33% 2019-02-28
Northern Trust Corp 1797889 1.04% 124331 7.43% 2018-09-30
Janus Capital Management LLC 2476115 1.43% -415037 -14.36% 2018-12-31
BlackRock Institutional Trust Company NA 3856787 2.23% -477502 -11.02% 2018-06-30
Amvescap Plc. 2115415 1.22% 597259 39.34% 2018-06-30
JPMorgan Chase & Co 2139269 1.24% 872354 68.86% 2018-06-30
Bridger Management LLC 1134414 0.66% 465922 69.70% 2018-06-30
Security Investors, LLC 1007609 0.53% 2275 0.23% 2018-09-14
Invesco PowerShares Capital Mgmt LLC 1249294 0.72% 960623 332.77% 2018-06-30
Goldman, Sachs & Co. 1338638 0.78% 67921 5.35% 2018-06-30
Millennium Management LLC 1468593 0.85% 391765 36.38% 2018-06-30
Northern Trust Investments N A 1680040 0.97% -925778 -35.53% 2018-06-30
T. Rowe Price Associates, Inc. 1924277 1.12% -1233956 -39.07% 2018-06-30
State Street Corp 6003908 3.48% -322695 -5.10% 2018-06-30
Merrill Lynch & Co Inc 595726 0.37% 336286 129.62% 2018-03-31
Eagle Asset Management, Inc. 1009601 0.62% -6491 -0.64% 2018-03-31
D. E. Shaw & Co LP 730167 0.45% 726274 18655.90% 2018-03-31
TIAA-CREF Investment Management LLC 644401 0.40% 18902 3.02% 2018-03-31
J.P. Morgan Investment Management Inc 762469 0.47% -87419 -10.29% 2018-03-31
Invesco Advisers, Inc 990959 0.61% -182553 -15.56% 2018-03-31
Westfield Capital Management Company, LP 1013932 0.62% -1279249 -55.78% 2018-03-31
Charles Schwab Investment Management Inc 1158240 0.71% 355766 44.33% 2018-03-31
Duquesne Family Office LLC 1192300 0.73% -641700 -34.99% 2018-03-31
Adage Capital Partners Gp LLC 1219087 0.75% 1080087 777.04% 2018-03-31
NORGES BANK 2424789 1.52% 72464 3.08% 2017-12-31
Principal Global Investors, LLC 1406257 0.88% -51750 -3.55% 2017-12-31
Federated Global Inv Mgmt Corp 1191400 0.75% 163200 15.87% 2017-12-31
Polar Capital LLP 975776 0.61% -42000 -4.13% 2018-01-31
Teachers Advisors Inc 930424 0.58% 256078 37.97% 2017-12-31
Rice Hall James & Associates, LLC 1029332 0.65% -207977 -16.81% 2017-12-31
OppenheimerFunds, Inc. 15094639 9.59% -9913681 -39.64% 2017-11-30
PointState Capital LP 1580300 1.01% -150700 -8.71% 2017-09-30
Artal Group S A 1250000 0.80% -150000 -10.71% 2017-09-30
Deutsche Bank AG 1226733 0.78% 748600 156.57% 2017-09-30
Rothschild Asset Management Inc 1182422 0.75% 56672 5.03% 2017-09-30
J P Morgan Asset Management (UK) Ltd 1144248 0.72% 4095 0.36% 2017-09-30
Charger Corp. 2083429 1.36% 2083429 -- 2016-12-31
Granahan Investment Management Inc.. 1993125 1.45% 12790 0.65% 2016-09-30
RA Capital Management, LLC 3664154 2.66% 439300 13.62% 2016-09-30
The Vanguard Group 8304449 4.00% 100483833 0.10% 1999-11-30
BlackRock, Inc. and certain subsidiaries 8643319 4.00% 104584160 0.10% 1999-11-30
OppenheimerFunds, Inc. and related entities 24200000 4.00% 292820000 0.20% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Vanguard Small Cap Growth Index Fund 1277575 0.73% 1277575 -- 2019-06-30
Invesco Oppenheimer Global Opports Fund 17300000 9.93% -- -- 2019-06-30
PrimeCap Odyssey Aggressive Growth Fund 10896376 6.25% -203400 -1.83% 2019-06-30
Vanguard Health Care Fund 10074642 5.78% 1891700 23.12% 2019-03-31
PrimeCap Odyssey Growth Fund 6735758 3.86% -24000 -0.36% 2019-06-30
Vanguard Total Stock Market Index Fund 4787910 2.75% 834 0.02% 2019-06-30
Fidelity Growth Company Commingled Pool 4249620 2.44% -- -- 2019-06-30
Invesco Oppenheimer Intl Sml-Mid Com Fd 3848681 2.21% 461011 13.61% 2019-06-30
Vanguard 500 Index Fund 3431184 1.97% 41603 1.23% 2019-06-30
First Trust NYSE Arca Biotech Fund 2973737 1.71% -7166 -0.24% 2019-07-31
Vanguard Small Cap Index 2223233 1.28% 2223233 -- 2019-06-30
Vanguard Mid-Cap Index Fund 2125353 1.22% -2026335 -48.81% 2019-06-30
SPDR 1901672 1.09% 1785 0.09% 2019-07-31
iShares Nasdaq Biotechnology ETF 1720687 0.99% 17855 1.05% 2019-07-30
Vanguard Institutional Index Fund 1626406 0.93% -9823 -0.60% 2019-06-30
Vanguard US Opportunities Fund 1458288 0.84% -36000 -2.41% 2019-06-30
Fidelity 1411517 0.81% 22444 1.62% 2019-06-30
iShares Core S&P 500 ETF 1254387 0.72% 2415 0.19% 2019-06-28
Vanguard Growth Index Fund 1197508 0.69% 1296 0.11% 2019-05-31
iShares Core S&P US Total Market ETF 1280952 0.73% 1155 0.09% 2019-05-30
iShares Core MSCI Kokusai ETF 1280952 0.73% 1155 0.09% 2019-05-30
Oppenheimer Global Opportunities Fund 17300000 9.93% -- -- 2019-03-31
Vanguard Mid-Cap Growth Index Fund 1045023 0.60% 37286 3.70% 2019-03-31
Fidelity Advisor 1080000 0.62% 80000 8.00% 2019-01-31
iShares Russell 2000 Growth ETF 1511584 0.87% 2606 0.17% 2018-06-21
OH Putnam Fidelity Spartan 500 Index 1296678 0.74% 37521 2.98% 2019-01-31
iShares S&P Small-Cap 600 Growth ETF 2129601 1.23% -- -- 2018-03-15
Vanguard Extended Market Index Fund 2022538 1.17% 11167 0.56% 2018-02-28
Vanguard Small Cap Index Fund 1945264 1.12% 16499 0.86% 2018-05-31
Vanguard Mid-Cap Growth ETF 1039673 0.60% 2250 0.22% 2018-07-31
Fidelity Spartan 1073238 0.62% 12658 1.19% 2018-07-31
Vanguard Growth Index Inv 1206314 0.70% -3360 -0.28% 2018-07-31
Vanguard Institutional Index I 1558609 0.90% 4049 0.26% 2018-07-31
First Trust NYSE Arca Biotech ETF 1524419 0.82% -- -- 2018-09-13
iShares Nasdaq Biotechnology 1944350 1.07% -3702 -0.19% 2018-09-12
Vanguard 500 Index Inv 2918913 1.69% 6615 0.23% 2018-07-31
Vanguard Mid Cap Index I 4067907 2.36% 27617 0.68% 2018-07-31
Vanguard Total Stock Mkt Idx 4306448 2.50% 17168 0.40% 2018-07-31
Vanguard Health Care Inv 5364813 3.11% 4030213 301.98% 2018-06-30
PRIMECAP Odyssey Growth 7146656 4.15% -58815 -0.82% 2018-06-30
PRIMECAP Odyssey Aggressive Growth 11934676 6.92% -138958 -1.15% 2018-06-30
Oppenheimer Global Opportunities A 12000000 6.96% 439984 3.81% 2018-07-31
Health Care Select Sector SPDR 816666 0.48% -207 -0.03% 2018-09-05
Janus Triton D 905084 0.56% -539914 -37.36% 2018-03-31
Janus Forty S 946982 0.58% 946982 -- 2018-03-31
Janus Research D 853400 0.53% 853400 -- 2018-03-31
Janus Global Life Sciences D 736147 0.45% -189512 -20.47% 2018-03-31
T. Rowe Price Health Sciences 1548100 0.95% 1548100 -- 2018-03-31
Vanguard Small Cap Growth Index Inv 1102941 0.64% 2302 0.21% 2018-05-31
iShares Russell 2000 Growth 1334789 0.88% 2594 0.19% 2018-06-01
Eagle Small Cap Growth A 720425 0.45% 123541 20.70% 2018-03-31
Principal SmallCap S&P 600 Idx SP 913676 0.57% -- -- 2018-02-28
Vanguard Tax-Managed Small Cap Adm 1214966 0.75% 4300 0.36% 2018-02-28
Vanguard Extended Market Idx Inv 2022538 1.26% 11167 0.56% 2018-02-28
Columbia Small Cap Index Z 796900 0.50% -- -- 2018-02-28
iShares S&P Small-Cap 600 Growth 2129601 1.60% 117173 5.82% 2018-03-14
Federated Kaufmann R 1000000 0.63% 70000 7.53% 2017-12-31
T. Rowe Price QM US Small-Cap Growth Eq 861000 0.55% 117200 15.76% 2017-12-31
PowerShares S&P SmallCap Health Care ETF 444059 0.37% -- -- 2018-01-25
Dreyfus Small Cap Stock Index 483079 0.31% -- -- 2017-11-30
CREF Stock R1 435762 0.28% 163361 59.97% 2017-11-30
TIAA-CREF Small-Cap Equity Instl 448300 0.28% 117300 35.44% 2017-11-30
Invesco Small Cap Growth A 1057083 0.67% 1636 0.16% 2017-09-30
Vanguard Explorer Inv 1242100 0.90% -38500 -3.01% 2016-09-30
JNL/Invesco Small Cap Growth B 848035 0.62% 20256 2.45% 2016-09-30
iShares S&P Small-Cap 600 Value 934555 0.67% 1307 0.14% 2017-02-07
Janus Global Life Sciences Fund 1474201 1.10% 326124 28.40% 2015-09-30
SPDR® S&P Pharmaceuticals ETF 1711736 1.60% -- -- 2015-11-19
BlackRock Health Sciences Opps Port 1999200 1.50% -- -- 2015-10-31
iShares Russell 2000 (AU) 2084327 2.00% -2628 -0.10% 2015-11-19
Vanguard US Opportunities 2308400 1.70% -- -- 2015-07-31
iShares Core S&P Small-Cap (AU) 3428599 3.20% 4616 0.10% 2015-11-19
Federated Kaufmann Fund 3500000 2.60% -- -- 2015-09-30
Oppenheimer Global Opportunities 26400000 19.80% -- -- 2015-09-30

Robert B. Chess Robert B. Chess is a businessperson who founded Penederm, Inc. and Biota Technology, Inc. and who has been the head of 7 different companies. Currently, Mr. Chess occupies the position of Chairman of Biota Technology, Inc. and Chairman at Nektar Therapeutics. Mr. Chess is also on the board of 7 other companies. Robert B. Chess previously was Chairman of Germitec SA, Associate Director-White House Office at Intel Corp., Chairman at OPX Biotechnologies, Inc., President for Penederm, Inc. and Principal at Metaphor Computer Systems, Inc. Mr. Chess received an undergraduate degree from California Institute of Technology and an MBA from Harvard University.
Nevan Charles Elam Founder of E2open LLC, Rezolute, Inc. and Konus Advisory Group, Inc., Nevan Charles Elam currently is Chairman & Chief Executive Officer of Rezolute, Inc. He is also on the board of Nektar Therapeutics, Softhale SPRL, pH Pharma Co. Ltd. and Savara, Inc. He previously occupied the position of Managing Director at Konus Advisory Group, Inc., President, Chief Executive Officer & Director at AeroSurgical Ltd., Partner at Wilson Sonsini Goodrich & Rosati PC, Senior Vice President-Pulmonary Business Unit at Nektar Therapeutics and Chief Financial Officer & VP-Business Development at E2open LLC. Nevan Charles Elam received an undergraduate degree from Howard University and a graduate degree from Harvard Law School.
Mary Tagliaferri Founder of Bionovo, Inc., Mary Tagliaferri currently is Chief Medical Officer of Nektar Therapeutics. In the past Dr. Tagliaferri held the position of President, Secretary, Treasurer & Director at Bionovo, Inc. and Secretary, Treasurer & Chief Regulatory Officer at Lighten Up Enterprises International, Inc. (a subsidiary of Bionovo, Inc.) and Chief Medical Officer for Kanglaite USA, Inc. Mary Tagliaferri received an undergraduate degree from Cornell University, a doctorate from The University of California, San Francisco and a graduate degree from American College of Traditional Chinese Medicine.
Ivan Philip Gergel Dr. Ivan P. Gergel is an Independent Non-Executive Director at Realm Therapeutics Plc, a Director & Managing Director at Corium International, Inc. and a Chief Medical Officer & Senior VP-Drug Development at Nektar Therapeutics. He is on the Board of Directors at Realm Therapeutics Plc, Corium International, Inc. and Life Sciences Pennsylvania. Dr. Gergel was previously employed as a Chief Scientific Officer by Endo Health Solutions, Inc., a Chief Scientific Officer by Endo Pharmaceuticals, Inc., a Senior Vice President-Scientific Affairs by Forest Laboratories, Inc., a President by Forest Research Institute, Inc., a VP-Clinical Development & Clinical Affairs by GlaxoSmithKline LLC, a Chief Scientific Officer & Executive VP by Endo International Plc, and an Independent Director by The Trendlines Group Ltd. He also served on the board at Penwest Pharmaceuticals Co., HealthTronics, Inc., Indevus Pharmaceuticals, Inc. and PhRMA Foundation. He received his MBA from The Wharton School of the University of Pennsylvania and a doctorate degree from UCL Medical School.
Christopher A. Kuebler Christopher A. Kuebler is on the board of Waters Corp. and Nektar Therapeutics. In his past career Mr. Kuebler was Vice President-European Operations at Abbott Laboratories and Chairman at Covance, Inc. He received an undergraduate degree from Florida State University.
R. Scott Greer Currently, Stephen K. Doberstein is Chief Research & Development Officer at Nektar Therapeutics. In the past Dr. Doberstein held the position of Vice President-Research at XOMA Corp. and Vice President-Research at XOMA (US) LLC (a subsidiary of XOMA Corp.), Vice President-Research at Xencor, Inc., Vice President-Research at Five Prime Therapeutics, Inc., Director-Pharmaceutical Target Research at Exelixis, Inc. and Engineer at E.I. du Pont de Nemours & Co. Stephen K. Doberstein received an undergraduate degree from the University of Delaware and a doctorate from The Johns Hopkins University School of Medicine.
Roy A. Whitfield Roy A. Whitfield founded Incyte Corp. He is on the board of Nektar Therapeutics and Station X, Inc. Mr. Whitfield previously occupied the position of Director at Incyte Corp., Advisor at InterWest Partners, LLC, Principal at The Boston Consulting Group, Inc., Principal at Technicon Instruments Corp., Principal at Cooper Biomedical, Inc. and Executive Chairman for BioSeek, Inc. He received an undergraduate degree from the University of Oxford and an MBA from Stanford University.
Karin Eastham Karin Eastham is on the board of Nektar Therapeutics, Geron Corp., Veracyte, Inc. and San Diego Athena. She previously occupied the position of Vice President-Finance & Administration at Paper Art Co., Inc., CFO, Secretary & Senior Vice President-Finance at Diversa Corp., CFO, Secretary & Senior Vice President-Finance at Cytel Corp., Vice President-Finance at Roche Diagnostics Corp., CFO, Secretary & Senior Vice President-Finance at CombiChem, Inc., Vice President-Finance & Administration at Pritsker Corp, Vice President-Finance at Boehringer Mannheim Diagnostics Corp. and Chief Operating Officer, Trustee & Executive VP at Sanford Burnham Prebys Medical Discovery Institute. She received an MBA and an undergraduate degree from Indiana University.
Robert B. Chess Robert B. Chess is a businessperson who founded Penederm, Inc. and Biota Technology, Inc. and who has been the head of 7 different companies. Currently, Mr. Chess occupies the position of Chairman of Biota Technology, Inc. and Chairman at Nektar Therapeutics. Mr. Chess is also on the board of 7 other companies. Robert B. Chess previously was Chairman of Germitec SA, Associate Director-White House Office at Intel Corp., Chairman at OPX Biotechnologies, Inc., President for Penederm, Inc. and Principal at Metaphor Computer Systems, Inc. Mr. Chess received an undergraduate degree from California Institute of Technology and an MBA from Harvard University.
Jillian B. Thomsen Currently, Jillian B. Thomsen holds the position of Chief Accounting Officer & Senior VP-Finance at Nektar Therapeutics. Ms. Thomsen previously occupied the position of Senior Manager at Arthur Andersen LLP and VP-Finance & Deputy Corporate Controller at Calpine Corp. Jillian B. Thomsen received a graduate degree from the University of Denver and an undergraduate degree from Colorado College.
Howard W. Robin Presently, Howard W. Robin is President, Chief Executive Officer & Director at Nektar Therapeutics. Mr. Robin is also on the board of Fairleigh Dickinson University. In the past he occupied the position of Senior Associate at Arthur Andersen LLP, President, Chief Executive Officer & Director at Sirna Therapeutics, Inc., Vice President & General Manager at Berlex Laboratories, Inc. and Director-Business Planning & Development at Berlex, Inc. Howard W. Robin received an undergraduate degree from Fairleigh Dickinson University.
Stephen K. Doberstein Currently, Stephen K. Doberstein is Chief Research & Development Officer at Nektar Therapeutics. In the past Dr. Doberstein held the position of Vice President-Research at XOMA Corp. and Vice President-Research at XOMA (US) LLC (a subsidiary of XOMA Corp.), Vice President-Research at Xencor, Inc., Vice President-Research at Five Prime Therapeutics, Inc., Director-Pharmaceutical Target Research at Exelixis, Inc. and Engineer at E.I. du Pont de Nemours & Co. Stephen K. Doberstein received an undergraduate degree from the University of Delaware and a doctorate from The Johns Hopkins University School of Medicine.
Lutz Lingnau Lutz Lingnau is on the board of Nektar Therapeutics. In his past career Mr. Lingnau occupied the position of Chairman for Micropharma Ltd., Chairman at Berlex Laboratories, Inc., Vice Chairman, President & Chief Executive Officer at Schering Berlin, Inc. and Member-Executive Board at Bayer Schering Pharma AG.
Gilbert M. Labrucherie Founder of Senova Systems, Inc., Gilbert M. Labrucherie is Chief Financial Officer & Senior Vice President of Nektar Therapeutics. Mr. Labrucherie is also Member of The State Bar of California. In the past he was Associate for Graham & James LLP, Associate at Wilson Sonsini Goodrich & Rosati PC, Chairman & Secretary at Chadmoore Wireless Group, Inc., Senior Director-Corporate Development at AltaVista Co., Vice President-Corporate Development of E2open LLC, Member of The Order of the Coif, Member of California Law Review and Director at Senova Systems, Inc. Mr. Labrucherie received an undergraduate degree from the University of California, Davis and a graduate degree from Berkeley Law University of California.
Jennifer Ruddock Currently, Jennifer Ruddock occupies the position of Senior VP-Investor Relations & Corporate Affairs at Nektar Therapeutics. Ms. Ruddock received an undergraduate degree from Colgate University.
Jeffrey Robert Ajer Jeffrey Robert Ajer is on the board of Nektar Therapeutics and True North Therapeutics, Inc. and Chief Commercial Officer & Executive VP of BioMarin Pharmaceutical, Inc. In his past career Mr. Ajer held the position of Chief Commercial Officer & Executive VP of BioMarin Pharmaceutical, Inc., Vice President-Global Transplant Operations at Genzyme Corp., Director-Purchasing Worldwide at Valeant Pharmaceuticals International Corp. and Senior Director-Sales Operations, Bids & Contracts at SangStat Medical Corp. Mr. Ajer received an MBA and an undergraduate degree from the University of California, Irvine.
John Nicholson John Nicholson occupies the position of Chief Operating Officer & Senior Vice President of Nektar Therapeutics. In his past career Mr. Nicholson occupied the position of President for Schering Berlin Insurance Co., President for Schering Berlin Capital Corp., President for Schering Berlin Venture Corp., President of Bayer Pharma Chemicals Co., Treasurer & Vice President-Corporate Development at Schering Berlin, Inc. and Treasurer of Berlex, Inc. He received an undergraduate degree from the University of Toledo (Ohio).
Dorian Hirth Presently, Dorian Hirth is Senior VP-Human Resources & Facilities Operations at Nektar Therapeutics. In the past she occupied the position of Vice President-Human Resources & Facilities at Corgentech, Inc. and Vice President-Human Resources & Facilities at Kosan Biosciences, Inc.
Jillian B. Thomsen Currently, Jillian B. Thomsen holds the position of Chief Accounting Officer & Senior VP-Finance at Nektar Therapeutics. Ms. Thomsen previously occupied the position of Senior Manager at Arthur Andersen LLP and VP-Finance & Deputy Corporate Controller at Calpine Corp. Jillian B. Thomsen received a graduate degree from the University of Denver and an undergraduate degree from Colorado College.
Dorian Hirth Presently, Dorian Hirth is Senior VP-Human Resources & Facilities Operations at Nektar Therapeutics. In the past she occupied the position of Vice President-Human Resources & Facilities at Corgentech, Inc. and Vice President-Human Resources & Facilities at Kosan Biosciences, Inc.
Dorian Hirth Presently, Dorian Hirth is Senior VP-Human Resources & Facilities Operations at Nektar Therapeutics. In the past she occupied the position of Vice President-Human Resources & Facilities at Corgentech, Inc. and Vice President-Human Resources & Facilities at Kosan Biosciences, Inc.
Mark A. Wilson Presently, Mark A. Wilson holds the position of Secretary, Senior Vice President & General Counsel of Nektar Therapeutics. He is also Member of The State Bar of California. In the past he occupied the position of Associate for Reed & Associates, Inc. He received a graduate degree from Seton Hall University and an undergraduate degree from Rutgers State University of New Jersey.
Brian L. Kotzin Brian L. Kotzin is on the board of Rigel Pharmaceuticals, Inc. and Senior Vice President-Clinical Development at Nektar Therapeutics. In the past Dr. Kotzin held the position of Vice President-Global & Clinical Development at Amgen, Inc. and Director-Autoimmunity Centre of Excellence at the University of Colorado Health Sciences Center. Dr. Kotzin received an undergraduate degree from the University of Southern California and a doctorate from Stanford University.
Jonathan Zalevsky Jonathan Zalevsky holds the position of Chief Scientific Officer at Nektar Therapeutics. In the past Dr. Zalevsky occupied the position of Global Vice President at Takeda Pharmaceuticals U.S.A., Inc. Dr. Zalevsky received an undergraduate degree from The University of Colorado Boulder.
Lisa L. Decker Dr. Lisa L. Decker is a Chief Business Officer at Atreca, Inc. and a Vice President-Business Development at Nektar Therapeutics. Dr. Decker was previously employed as an Associate Director-Technology Licensing by University of Massachusetts Medical School. She received her doctorate degree from Tufts University School of Medicine.
Wei Lin Wei Lin is Senior Vice President-Clinical Development at Nektar Therapeutics. Dr. Lin received an undergraduate degree from Haverford College and a graduate degree from Harvard Medical School.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐